drugset / Trial / NCT00199888
Safety Study With the Antibody, cG250, and Isotope, 124-Iodine, to Diagnose Patients With Renal Masses.
Phase 1
Completed
26 enrolled
Ludwig Institute for Cancer Research
Memorial Sloan Kettering Cancer Center · collab
NaSingle-groupOpen-labelDiagnostic
Summary
The purpose of this study is to see if an antibody (cG250) attached to a radioactive substance (Iodine-124) safely detects clear cell renal cancer in patients with kidney tumors scheduled for surgery.
Timeline
- Start
- 2005-06
- Primary completion
- 2006-03
- Completion
- 2009-05-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | girentuximab | Monoclonal antibody | 10 mg | Intravenous |
| Subject | girentuximab | Monoclonal antibody | 185 mbq | Intravenous |